t(3;21) following peripheral blood stem cell transplantation in chronic phase chronic myeloid leukaemia.
A 40-year-old male with Ph-positive CML underwent PBSC autografting after initial treatment with hydroxyurea and interferon. Following autograft he remained in chronic phase with cytogenetic or molecular evidence of low levels of residual Ph-positive cells. However, additional cytogenetic abnormalities, including t(3;21) typically seen in therapy-related myelodysplastic syndrome (MDS) and AML and blast crisis of CML, developed as an independent cell line following the autograft. More than 4 years after the autograft, the patient remains in chronic phase with no evidence of accelerated phase or blast crisis of CML, but with a concurrent MDS. We report a case of CML who developed therapy-related MDS following PBSC autograft while still remaining in chronic phase.
Jacob
A
A
Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK.
Griffiths
M
M
Larkins
S
S
Holmes
J
J
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002871:Chromosome Banding; D002891:Chromosomes, Human, Pair 21; D002893:Chromosomes, Human, Pair 3; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000628:therapy*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy / Q000235:genetics* / Q000628:therapy*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000209:etiology / Q000235:genetics; D013997:Time Factors; D014178:Translocation, Genetic; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents; D007372:Interferons; D006918:Hydroxyurea